MCID: SQM002
MIFTS: 38

Squamous Cell Papilloma

Categories: Cancer diseases, Oral diseases, Skin diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Squamous Cell Papilloma

MalaCards integrated aliases for Squamous Cell Papilloma:

Name: Squamous Cell Papilloma 11 14 75
Papilloma 43 71
Papilloma, Squamous Cell 71
Epidermoid Papilloma 11

Classifications:



External Ids:

Disease Ontology 11 DOID:139
MeSH 43 D010212
NCIt 49 C3712
SNOMED-CT 68 63451008
UMLS 71 C0030354 C0205874

Summaries for Squamous Cell Papilloma

MalaCards based summary: Squamous Cell Papilloma, also known as papilloma, is related to bladder transitional cell papilloma and skin papilloma. An important gene associated with Squamous Cell Papilloma is TP53 (Tumor Protein P53), and among its related pathways/superpathways are T-cell activation SARS-CoV-2 and Malignant pleural mesothelioma. The drugs Chlorhexidine and Polihexanide have been mentioned in the context of this disorder. Affiliated tissues include cervix, tongue and skin.

Wikipedia: 75 A squamous cell papilloma is a generally benign papilloma that arises from the stratified squamous... more...

Related Diseases for Squamous Cell Papilloma

Diseases related to Squamous Cell Papilloma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1054)
# Related Disease Score Top Affiliating Genes
1 bladder transitional cell papilloma 32.3 TP53 KRT7 HRAS
2 skin papilloma 32.2 TP53 HRAS
3 transitional papilloma 32.2 KRT7 H2BC1
4 larynx squamous papilloma 32.1 TP53 HRAS CDKN2A
5 inverted transitional papilloma 32.1 KRT7 CDKN2A
6 urinary tract papillary transitional cell benign neoplasm 31.9 TP53 KRT7 HRAS
7 focal epithelial hyperplasia 31.8 TP53 GP5
8 anogenital venereal wart 31.7 TP53 GP5 CDKN2A
9 lip and oral cavity cancer 31.7 TP53 HRAS CDKN2A
10 human papillomavirus infectious disease 31.7 TP53 HRAS GP5 CDKN2A
11 keratosis, seborrheic 31.5 TP53 KRT7 CDKN2A
12 papilloma 31.5 TP53 KRT7 CDKN2A
13 li-fraumeni syndrome 31.5 TP53 HRAS CDKN2A
14 papillary adenoma 31.5 TP53 KRT7 HRAS H2BC1
15 suppressor of tumorigenicity 3 31.4 TP53 CDKN2A
16 vulva squamous cell carcinoma 31.3 TP53 HRAS GP5 CDKN2A
17 cervicitis 30.8 GP5 CDKN2A
18 laryngeal benign neoplasm 30.7 TP53 CDKN2A
19 adenocarcinoma 30.6 TP53 KRT7 HRAS CDKN2A
20 cervix uteri carcinoma in situ 30.5 TP53 GP5 CDKN2A
21 penile cancer 30.5 TP53 GP5 CDKN2A
22 skin benign neoplasm 30.5 TP53 KRT7 HRAS
23 epidermodysplasia verruciformis 1 30.5 TP53 GP5 CDKN2A
24 penile benign neoplasm 30.5 TP53 GP5 CDKN2A
25 papillary transitional carcinoma 30.4 TP53 KRT7
26 bladder urothelial carcinoma 30.4 TP53 HRAS CDKN2A
27 chronic cervicitis 30.4 TP53 GP5 CDKN2A
28 conjunctival squamous cell carcinoma 30.4 TP53 CDKN2A
29 skin carcinoma 30.4 TP53 KRT7 HRAS CDKN2A
30 skin squamous cell carcinoma 30.4 TP53 HRAS CDKN2A
31 gallbladder disease 30.3 TP53 KRT7 HRAS
32 glandular cystitis 30.3 TP53 KRT7
33 papillary adenocarcinoma 30.2 TP53 KRT7 HRAS
34 basaloid squamous cell carcinoma 30.2 TP53 KRT7 CDKN2A
35 sinonasal undifferentiated carcinoma 30.2 KRT7 CDKN2A
36 cervical adenocarcinoma 30.2 TP53 KRT7 CDKN2A
37 teratoma 30.2 TP53 KRT7 CDKN2A
38 keratosis 30.1 TP53 HRAS CDKN2A
39 squamous cell carcinoma 30.1 TP53 KRT7 HRAS CDKN2A
40 lymphoepithelioma-like carcinoma 30.1 TP53 KRT7 CDKN2A
41 anal squamous cell carcinoma 30.1 TP53 KRT7 CDKN2A
42 cystic teratoma 30.1 TP53 KRT7
43 bladder adenocarcinoma 30.1 TP53 KRT7
44 verrucous carcinoma 30.1 TP53 GP5 CDKN2A
45 anus cancer 30.1 TP53 KRT7 HRAS GP5 CDKN2A
46 hypopharynx cancer 30.1 TP53 CDKN2A
47 barrett esophagus 30.0 TP53 KRT7 CDKN2A
48 adenoid squamous cell carcinoma 30.0 TP53 KRT7
49 hemangioma 30.0 TP53 KRT7 CDKN2A
50 appendix adenocarcinoma 30.0 TP53 KRT7 HRAS

Graphical network of the top 20 diseases related to Squamous Cell Papilloma:



Diseases related to Squamous Cell Papilloma

Symptoms & Phenotypes for Squamous Cell Papilloma

Drugs & Therapeutics for Squamous Cell Papilloma

Drugs for Squamous Cell Papilloma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 177)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Chlorhexidine Approved, Vet_approved, Withdrawn Phase 4 55-56-1 2713 9552079
2
Polihexanide Approved, Investigational Phase 4 28757-47-3 20977
3
Cidofovir Approved Phase 4 113852-37-2 60613
4
Racepinephrine Approved, Vet_approved Phase 4 51-43-4, 329-65-7 838 5816
5
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
6 Biguanides Phase 4
7 Hypoglycemic Agents Phase 4
8 Disinfectants Phase 4
9 Anti-Infective Agents, Local Phase 4
10 Chlorhexidine gluconate Phase 4
11 Immunoglobulins Phase 4
12 Antibodies Phase 4
13 Epinephryl borate Phase 4
14 Bronchodilator Agents Phase 4
15 Adrenergic beta-Agonists Phase 4
16 Adrenergic alpha-Agonists Phase 4
17 Adrenergic Agonists Phase 4
18 Anti-Asthmatic Agents Phase 4
19 Sodium Channel Blockers Phase 4
20 Vasoconstrictor Agents Phase 4
21 Anesthetics, Local Phase 4
22 Respiratory System Agents Phase 4
23 Mydriatics Phase 4
24 Sympathomimetics Phase 4
25 Diuretics, Potassium Sparing Phase 4
26 Vaccines Phase 3
27
Erlotinib Approved, Investigational Phase 1, Phase 2 183319-69-9, 183321-74-6 176870
28
Avelumab Approved, Investigational Phase 2 1537032-82-8
29
Mycophenolic acid Approved, Investigational Phase 2 24280-93-1 446541
30
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
31
Clotrimazole Approved, Vet_approved Phase 2 23593-75-1 2812
32
Masoprocol Approved, Investigational Phase 1, Phase 2 500-38-9, 27686-84-6 71398
33
Cianidanol Approved, Withdrawn Phase 2 154-23-4 9064
34
Lenograstim Approved, Investigational Phase 2 135968-09-1
35
Nivolumab Approved Phase 2 946414-94-4
36
Hydroxyurea Approved Phase 2 127-07-1 3657
37
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
38
Durvalumab Approved, Investigational Phase 2 1428935-60-7
39
Nelfinavir Approved Phase 2 159989-64-7 64143
40
Lenvatinib Approved, Investigational Phase 2 417716-92-8 9823820
41
Pembrolizumab Approved Phase 2 1374853-91-4 254741536
42
Cetuximab Approved Phase 2 205923-56-4
43
Fluorouracil Approved Phase 2 51-21-8 3385
44
Carboplatin Approved Phase 2 41575-94-4 10339178 38904
45
Cisplatin Approved Phase 2 15663-27-1 2767 5702198 441203
46
Celecoxib Approved, Investigational Phase 2 169590-42-5 2662
47
Panitumumab Approved, Investigational Phase 2 339177-26-3
48
Docetaxel Approved, Investigational Phase 2 114977-28-5 148124
49
Vitamin A Approved, Nutraceutical, Vet_approved Phase 2 22737-96-8, 68-26-8 5280382 445354
50
Aspartic acid Approved, Nutraceutical Phase 1, Phase 2 56-84-8 5960

Interventional clinical trials:

(show top 50) (show all 262)
# Name Status NCT ID Phase Drugs
1 Immunogenicity, Compliance, Knowledge and Attitudes in Postpartum Women During a Two Dose 9-valent HPV Vaccination Series Unknown status NCT04311528 Phase 4
2 Immunogenicity and Safety of Human Papilloma Virus Vaccine in Solid Organ Transplant Recipients Completed NCT02624349 Phase 4 Quadravalent human papillomavirus vaccine
3 Antisepsis Regimen in the Surgical Treatment of Human Papilloma Virus Generated Cervical Lesions: Polyhexamethylene Biguanide Versus Chlorhexidine Completed NCT01740245 Phase 4
4 Study of the Impact of a School Program Combining - Promotion of HPV Vaccination and HPV Vaccine Offer in Middle School - on Adherence to HPV Vaccination in Middle School Students Completed NCT04459221 Phase 4 Gardasil 9, 9-Valent Intramuscular Suspension
5 Use of Cidofovir Injection in the Treatment of Recurrent Respiratory Papillomatosis." Completed NCT00205374 Phase 4 Cidofovir;Placebo
6 Occupational Exposure to Human Papilloma Virus (HPV) and Prophylactic Vaccination (Version IV Dated 24Oct2017) Recruiting NCT03350698 Phase 4
7 Randomized, Placebo-controlled, Double-blind Study to Evaluate 2LPAPI® Efficacy on the Clearance of Genital HR-HPV Infections. Recruiting NCT04232917 Phase 4 2LPAPI®;Placebo
8 GARDASIL 9: 3 Dose vs. 2 Dose With Delayed 3rd Dose Recruiting NCT03943875 Phase 4
9 Immunogenicity and Safety of Concomitant Inoculation of Recombinant Human Papillomavirus Bivalent (Types 16,18) Vaccine (Escherichia Coli) and Measles Mumps and Rubella Combined Vaccine, Live Active, not recruiting NCT05279248 Phase 4
10 Study on the Immunogenicity and Safety of Co-immunization With Recombinant Human Papillomavirus 16/18 Bivalent Vaccine and Hepatitis E Vaccine Active, not recruiting NCT05415345 Phase 4
11 A Pilot Study of the Immunogenicity of a Two-dose Protocol for 9-valent Human Papilloma Virus Vaccination in Postpartum Girls and Women (15-45 Years Old) Previously Unvaccinated Against HPV Active, not recruiting NCT04274153 Phase 4
12 Prospective Longitudinal Study on Immunogenicity, Induction of Cellular Immune Responses and Safety of Vaccination Against HPV With the 9-valent Vaccine in HIV-positive Women (The Papillon Study) Active, not recruiting NCT03391921 Phase 4
13 Bacteriostatic Saline as a Local Anesthetic in Minor Eyelid Procedures Not yet recruiting NCT05294640 Phase 4 0.9% Bacteriostatic Local Anesthetic Injection;1% Lidocaine with 1:100,000 epinephrine Local Anesthetic Injection
14 Immunogenicity of 9-valent HPV Vaccine in Immunocompromised Children and Adolescents Not yet recruiting NCT05439083 Phase 4
15 Assessment of the Safety, Side Effects and Efficacy of Interventional Cryotherapy for the Eradication of Benign Airway Disease("ICE THE BAD") Terminated NCT00747461 Phase 4
16 The Impact of Co-infections on Inflammation in Patients Commencing Second-line Antiretroviral Therapy. A Sub-study of D²EFT (Dolutegravir and Darunavir Evaluation in Adults Failing Therapy) Withdrawn NCT04183738 Phase 4 NRTIs;Darunavir;Ritonavir;Dolutegravir
17 Anal Dysplasia Study of Men Who Have Sex With Men Living With HIV Withdrawn NCT01663558 Phase 4 imiquimod
18 A Phase III Double Blinded, Randomized Controlled Study to Evaluate Efficacy of Protection Against HPV-16 and 18 Related Diseases, Immunogenicity and Safety of HPV-16/18 Vaccine in Healthy Females Aged 18-30 Years Unknown status NCT02733068 Phase 3
19 Efficacy Study of the Quadrivalent Human Papilloma Virus (HPV) Vaccine to Prevent Recurrence of External Genital Warts (EGW) in Patients Who Were Cured in the First Place Unknown status NCT03296397 Phase 3
20 Evaluation of a Two-dose Schedule of Quadrivalent Human Papilloma Virus (Types 6, 11, 16, 18) Recombinant Vaccine in 11-year-old Boys in Mexico City (Gardasil® Merck and Co.). Unknown status NCT02382900 Phase 3
21 Phase III, Single-center Clinical Trial to Evaluate the 4-valent HPV Vaccine for the Treatment and Prevention of Recurrent Respiratory Papillomatosis in Children Unknown status NCT01995721 Phase 3
22 Prospective Non Controlled Study of Immunogenicity of Human Papilloma Virus (HPV) Vaccine in Groups at Special Risk of Poor Vaccine Result Completed NCT00964210 Phase 3 Licensed quadrivalent HPV vaccine, Gardasil
23 Safety, Immunogenicity, and Efficacy of Gardasil (V501 (Human Papilloma Virus [Types 6, 11, 16, 18] Recombinant Vaccine) in Mid-Adult Women - The FUTURE III (Females United to Unilaterally Reduce Endo/Ectocervical Cancer) Study Completed NCT00090220 Phase 3
24 Quadrivalent and Bivalent Human Papilloma Virus Vaccines in the Treatment of Common Recalcitrant Warts Completed NCT05383625 Phase 3 Quadrivalent Human Papillomavirus (Types 6,11,16,18) Recombinant Vaccine;Bivalent Human Papilloma Virus Vaccine;Saline
25 A Phase III Placebo-controlled Clinical Trial to Study the Tolerability, Immunogenicity and Efficacy of V501 in 16- to 26-year-old Japanese Men Completed NCT01862874 Phase 3
26 A Phase III, Open-Label, Clinical Trial to Study the Safety and Immunogenicity of the Quadrivalent HPV (Types 6, 11, 16, 18) L1 VLP Particle (VLP) Vaccine in 9- to 15-Year-Old Japanese Boys Completed NCT02576054 Phase 3
27 A Randomized, Double-Blinded, Controlled With GARDASIL (Human Papillomavirus Vaccine [HPV] [Types 6, 11, 16, 18] (Recombinant, Adsorbed)), Phase 3 Clinical Trial to Study the Immunogenicity and Tolerability of V503 (9-Valent Human Papillomavirus L1 Virus-Like Particle [VLP] Vaccine) in 16- to 26-year-old Men Completed NCT02114385 Phase 3
28 An Open-label Phase III Study to Investigate the Safety, Tolerability and Immunogenicity of a Nine-valent Human Papillomavirus (HPV) Vaccine (Gardasil®9) in Solid Organ Transplant Recipients and HIV-infected Patients Completed NCT03525210 Phase 3
29 Phase IIIb Study of Recombinant Tetravalent HPV Vaccine in Patients With Recurrent Respiratory Papillomatosis Completed NCT01375868 Phase 3
30 The Effects of Probiotic Against Reducing Abundance of Human Papilloma Virus (HPV) in Women Recruiting NCT05316064 Phase 2, Phase 3
31 ANCHOR Study: Anal Cancer/HSIL Outcomes Research Study Active, not recruiting NCT02135419 Phase 3 imiquimod;fluorouracil
32 A Dose Reduction Immunobridging and Safety Study of Two HPV Vaccines in Tanzanian Girls Active, not recruiting NCT02834637 Phase 3 bivalent HPV vaccine;nonavalent HPV vaccine
33 Adjuvant Imiquimod Therapy to Reduce Recurrence Rate in Patients After Surgical Therapy of Anal HPV (Human Papilloma Virus)-Lesions Not yet recruiting NCT03289260 Phase 3 Imiquimod 5% cream;Placebo cream
34 A Study of Reduced Dosing of the Nonavalent HPV Vaccine in Women Living With HIV Not yet recruiting NCT05495906 Phase 3
35 Propranolol Administration in Pediatric Patients With Recurrent Respiratory Papillomatosis Withdrawn NCT01058317 Phase 2, Phase 3 Propranolol
36 Phase II Study of Immunotherapy With Autogenous Papilloma Vaccine in Patients With Recurrent Juvenile Papilloma of the Larynx Unknown status NCT00002454 Phase 2
37 Phase I/II and Multicenter Trial of HPV Specific Immune Lymphocytes (HPV-CTLs) in the Treatment of Human Papilloma Virus (HPV) Infection Unknown status NCT03351855 Phase 1, Phase 2
38 A Safety and Efficacy Trial of Circumferential Anal Canal Radiofrequency Ablation for High-Grade Anal Intraepithelial Neoplasia Using the BARRX™ Anorectal Wand Unknown status NCT03302858 Phase 2
39 Single Center, Placebo Controlled, Double-Blind Study to the Treatment of HPV Infected Cervix With AV2 Antiviral Spray and Assessment of Viral Load Unknown status NCT01654822 Phase 2 topical application cervical spray;topical spray on the cervix
40 Bevacizumab Versus Cidofovir for the Treatment of Recurrent Respiratory Papillomatosis: a Randomized, Double-blind, Placebo-controlled Clinical Trial Unknown status NCT02555800 Phase 2 Bevacizumab;Cidofovir
41 A Randomized Phase II Trial of Bevacizumab to Control Brain Radiation Damage Completed NCT00492089 Phase 2 bevacizumab;placebo
42 A Phase I, and Biologic Correlative Study of Erlotinib, in Combination With Cetuximab and Bevacizumab in Patients With Metastatic Renal Cell Carcinoma Completed NCT00101348 Phase 1, Phase 2 erlotinib hydrochloride
43 A Phase II Study of Avelumab in Subjects With Recurrent Respiratory Papillomatosis Completed NCT02859454 Phase 2 Avelumab
44 A Phase II Study of M7824 in Subjects With Recurrent Respiratory Papillomatosis Completed NCT03707587 Phase 2 M7824
45 Phase 1-2 18F-FPPRGD2 PET/CT or PET/MRI Imaging of αvβ3 Integrins Expression as a Biomarker of Angiogenesis Completed NCT01806675 Phase 1, Phase 2 18F-fludeoxyglucose (18F-FDG);18F-FPPRGD2
46 A Phase IIa Randomized, Double-Blind Controlled With Gardasil, Clinical Trial to Study theTolerability and Immunogenicity of V505 (a Multivalent Human Papilloma Virus [HPV] L1 Virus Like Particle [VLP] Vaccine) in Healthy 16 to 26 Year Old Women Completed NCT00520598 Phase 2 Comparator: V505 formulation 2
47 A Multicenter, Open Label Phase I/II Study to Determine the Safety and Immune Modulating Effects of the Therapeutic Human Papilloma Virus 16 (HPV16) E6/E7 Long Peptides Vaccine (ISA101/ISA101b) Immunotherapy in Combination With Standard of Care Therapy (Carboplatin and Paclitaxel With or Without Bevacizumab) in Women With HPV16 Positive Advanced or Recurrent Cervical Cancer Who Have no Curative Treatment Options Completed NCT02128126 Phase 1, Phase 2 ISA101/ISA101b
48 Pilot Study to Evaluate the Anti-Tumor Effect of Durvalumab (Medi4736) in Patients With Squamous Cell Carcinoma of the Head and Neck (SCCHN), Human Papilloma Virus (HPV) Positive Versus Negative, When Treated Before Surgery Completed NCT02827838 Phase 2
49 Phase II Pilot Trial of Non-Myeloablative Allogeneic Peripheral Blood Stem Cell (PBSC) Transplantation Using Fludarabine, Low Dose TBI and Post-Transplant Cyclosporine and Mycophenolate Mofetil Followed by Donor Lymphocyte Infusion for Therapy of Advanced or Metastatic Human Papilloma Virus (HPV) - Associated Cervical Carcinoma Refractory to Standard Therapy Completed NCT00005941 Phase 2 cyclosporine;fludarabine phosphate;mycophenolate mofetil
50 A Phase II Trial in Patients With Early Cervical Cancer to Study The Safety and The Immunological Effects of Vaccination With TA-HPV, A Live Recombinant Vaccinia Virus Expressing The Human Papilloma Virus 16 and 18 E6 and E7 Proteins Completed NCT00002916 Phase 2

Search NIH Clinical Center for Squamous Cell Papilloma

Inferred drug relations via UMLS 71 / NDF-RT 50 :


podophyllin
PODOPHYLLIN PWDR

Cochrane evidence based reviews: papilloma

Genetic Tests for Squamous Cell Papilloma

Anatomical Context for Squamous Cell Papilloma

Organs/tissues related to Squamous Cell Papilloma:

MalaCards : Cervix, Tongue, Skin, Endothelial, Breast, Lung, Eye

Publications for Squamous Cell Papilloma

Articles related to Squamous Cell Papilloma:

(show top 50) (show all 225)
# Title Authors PMID Year
1
Squamous cell papilloma a rare urinary bladder tumor, case report and operative video. 62
35444928 2022
2
Squamous Cell Papilloma of the Conjunctiva. 62
35803837 2022
3
Esophageal Squamous Cell Papilloma: A Report of Three Cases. 62
35733452 2022
4
Conjunctival epithelial hyperplasia in a patient with a nodular lesion in the palpebral conjunctiva: A case report. 62
35251611 2022
5
Clinicopathological feature of a resected large mixed squamous cell and glandular papilloma: A case report. 62
35306333 2022
6
[Clinical features of 19 cases of lower respiratory papillomatosis]. 62
35135087 2022
7
Eyelid Tumours in Northern Malaysia: A Five-Year Review. 62
35004082 2022
8
Conjunctival Rhinosporidiosis in an Ethiopian Child: A Case Report. 62
35982772 2022
9
Squamous Cell Papilloma of the Oesophagus: A Human Papilloma Virus Lesion. 62
34966610 2021
10
Squamous cell papilloma-like presentation of multiple neurovascular hamartomas of the oral cavity. 62
34818931 2021
11
[Esophageal squamous papilloma - a case report]. 62
34800026 2021
12
An evaluation of carcinogenicity predictors from short-term and sub chronic repeat-dose studies of agrochemicals in rats: Opportunities to refine and reduce animal use. 62
34364947 2021
13
Clinicopathological characteristics of patients with oesophageal squamous papilloma in Turkey and comparison with the literature data: The largest case series ever reported from Turkey. 62
34053176 2021
14
HPV-Associated Benign Squamous Cell Papillomas in the Upper Aero-Digestive Tract and Their Malignant Potential. 62
34452488 2021
15
Higher Number of EBI3 Cells in Mucosal Chronic Hyperplastic Candidiasis May Serve to Regulate IL-17-Producing Cells. 62
34209407 2021
16
[Squamous Cell Papilloma of the Urinary Bladder]. 62
33271658 2020
17
Squamous cell papilloma of the gingiva with a "garlanding a tooth" appearance: Report of an unusual case. 62
33424176 2020
18
Partial glossectomy for treating extensive oral squamous cell papilloma. 62
27544018 2020
19
Tracheal squamous cell papilloma with an aberrant artery in the stalk. 62
32170025 2020
20
Frequent KRAS and HRAS mutations in squamous cell papillomas of the head and neck. 62
31960612 2020
21
Malignant transformation of oral squamous cell papilloma: a case report. 62
32980707 2020
22
Squamous Cell Papilloma of the Esophagus: A Case Series Highlighting Endoscopic and Histologic Features. 62
32566329 2020
23
Demographic features and histopathological diagnosis in primary eyelid tumors: results over 19 years from a tertiary center in Ankara, Turkey. 62
32821684 2020
24
[A clinicopathological classification analysis of ocular mass lesions in 7 910 cases]. 62
31715682 2019
25
Squamous Cell Papilloma in a Student Aviator. 62
31666160 2019
26
Ulcerative Squamous Eyelid Papilloma: A Rare Presentation. 62
31875107 2019
27
Recurrence rate of oral squamous cell papilloma after excision with surgical scalpel or laser therapy: A retrospective cohort study. 62
31232385 2019
28
Squamous Cell Papillomatosis in the Setting of Recurrent Respiratory Papillomatosis. 62
29594918 2019
29
Giant Squamous Cell Papilloma of the Eyelid-Diagnostic and Therapeutic Challenges. 62
31781447 2019
30
Gastrointestinal: Esophageal squamous cell papilloma in a patient with Cronkhite-Canada syndrome. 62
30069941 2018
31
Lanthanum-Induced Mucosal Alterations in the Stomach (Lanthanum Gastropathy): a Comparative Study Using an Animal Model. 62
29302869 2018
32
Herpesvirus associated dermal papillomatosis in Williams' mud turtle Pelusios williamsi with effects of autogenous vaccine therapy. 62
29887582 2018
33
A solitary bronchial squamous cell papilloma with increased 18-fluorodeoxyglucose uptake and high serum levels of squamous cell carcinoma antigen. 62
30069399 2018
34
Endoscopic mucosal resection of rectal squamous cell papilloma. 62
29351698 2018
35
Laryngeal squamous cell papilloma is highly associated with human papillomavirus. 62
29447361 2018
36
Use of trichloroacetic acid for management of oral lesions caused by human papillomavirus. 62
29513235 2018
37
A retrospective study of 2228 cases with eyelid tumors. 62
30450316 2018
38
Safety of ethyl acrylate to be used as flavouring. 62
32625331 2017
39
Molecular characterization, prevalence and clinical relevance of Phodopus sungorus papillomavirus type 1 (PsuPV1) naturally infecting Siberian hamsters (Phodopus sungorus). 62
29022861 2017
40
Retrospective analysis of benign orofacial tumors at a tertiary referral center in Saudi Arabia. 62
28052640 2017
41
Giant Ocular Surface Squamous Cell Papilloma Treated With Topical Mitomycin C. 62
28715561 2017
42
Analyzing esophageal squamous cell papillomas for the presence of human papilloma virüs. 62
28316321 2017
43
[Solitary Peripheral Pulmonary Squamous Cell Papilloma;Diagnostic Significance of 18F-fluorodeoxyglucose Positron Emission Tomography Findings]. 62
28428529 2017
44
Esophageal Squamous Cell Papilloma. 62
27751518 2017
45
Nonmonotonic Pathway Gene Expression Analysis Reveals Oncogenic Role of p27/Kip1 at Intermediate Dose. 62
29162974 2017
46
Assessment of the incidence of squamous cell papilloma of the esophagus and the presence of high-risk human papilloma virus. 62
27001250 2017
47
Black raspberries demethylate Sfrp4, a WNT pathway antagonist, in rat esophageal squamous cell papilloma. 62
27696538 2016
48
Oral squamous papilloma occurring on the palate with review of literature. 62
27849344 2016
49
4-Methylthio-3-butenyl isothiocyanate (raphasatin) exerts chemopreventive effects against esophageal carcinogenesis in rats. 62
27821908 2016
50
Coexistence of squamous cell tracheal papilloma and carcinoma treated with chemotherapy and radiotherapy: a case report. 62
26730195 2016

Variations for Squamous Cell Papilloma

Expression for Squamous Cell Papilloma

Search GEO for disease gene expression data for Squamous Cell Papilloma.

Pathways for Squamous Cell Papilloma

GO Terms for Squamous Cell Papilloma

Biological processes related to Squamous Cell Papilloma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 Ras protein signal transduction GO:0007265 9.43 TP53 HRAS CDKN2A
2 cellular senescence GO:0090398 9.1 TP53 HRAS CDKN2A

Sources for Squamous Cell Papilloma

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....